Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Company Profile for Merck KGaA.


With a history that began 1668 in Darmstadt Darmstadt (därm`shtät), city (1994 pop. 139,750), Hesse, central Germany. It is a commercial, industrial, and transportation center; its manufactures include chemicals, machinery, and pharmaceuticals. , Germany, Merck is the world's oldest chemical-pharmaceutical company. With sales of EUR EUR

In currencies, this is the abbreviation for the Euro.

Notes:
The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion.
 5.9 billion in 2004 and a future shaped by 28,900 employees in 56 countries, its success is characterized char·ac·ter·ize  
tr.v. character·ized, character·iz·ing, character·iz·es
1. To describe the qualities or peculiarities of: characterized the warden as ruthless.

2.
 by innovations from entrepreneurial en·tre·pre·neur  
n.
A person who organizes, operates, and assumes the risk for a business venture.



[French, from Old French, from entreprendre, to undertake; see enterprise.
 employees. Merck's operating activities come under the umbrella of Merck KGaA This article needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. , in which the Merck family Friedrich Jacob Merck purchased the second town pharmacy in Darmstadt, known as the Engel-Apotheke or Angel Pharmacy. When Friedrich died, the pharmacy was passed on to his nephew and ever since has gone from father to son.  holds a 73% interest and free shareholders own the remaining 27%. The former U.S. subsidiary, Merck & Co., has been completely independent of the Merck Group since 1917.
Company:                  Merck KGaA

          Headquarters Address:     Frankfurter Str. 250
                                    Darmstadt D- 64293  Germany

          Main Telephone:           +49 6151 72 0

          Website:                  www.merck.de

          Ticker:                   MRK(FWB)

          Type of Organization:     Partnership limited by shares

          Industry:                 Health: Pharmaceuticals
                                    Chemicals: Liquid crystals,
                                    Pigments, Life Science & Analytics

          Earnings Release Dates:   4th Quarter 05: February 16, 2006


          Key Executives:           Chairman: Michael Roemer
                                    CFO: Michael Becker

          Public Relations
          Contact:                  Dr. Juergen Knackmuss
          Phone:                    +49 6151 72-2578
          Email:                    juergen.knackmuss@merck.de

          Public Relations
          Contact:                  Phyllis Carter
          Phone:                    +49 6151 72-7144
          Email:                    phyllis.carter@merck.de
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Company Profile
Geographic Code:4EUGE
Date:Dec 9, 2005
Words:176
Previous Article:It is Predicted by 2010 the Russian Mobile Market Will Have Grown by 40%.
Next Article:The Ukraine Seeks to Reduce Russia's Influence over Its Energy Supply Industry.
Topics:



Related Articles
Kos Receives Final Approval to Market Niaspan in France, Second Largest Market in Europe.
Dyax Corp. and Merck KGaA Enter Into License Agreement for Discovery of Therapeutic Antibodies and Peptides.
Merck KGaA Unveils Its Japan Business Reorganization Plan.
EMD Chemicals' Parent Company Recognized for Printed Electronics Breakthrough.
Cenix BioScience and Merck KGaA Sign Framework Agreement for RNAi-Based Drug Discovery.
Clinical Data Completes Vilazodone Manufacturing Technology Transfer Under License with Merck KGaA.
SLOAN CANCER VACCINE PHASE III STUDY BEGINS.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles